

## A novel fast and simple quantification method for bile acids in human serum by LC-MS/MS

## **MSACL 2017**

Aurore JAFFUEI, Sara SAMBISSA, Alban HUTEAU, SHIMADZU France, le Luzard 2, Bd Allende, 77186 Noisiel, FRANCE.



PO-CON1781E

A novel fast and simple quantification method for bile acids in human serum by LC-MS/MS

## Introduction

Bile Acids (BAs) are steroid acids of the bile. They are fat substances solubilizers of the enterohepatic cycle and are key players of lipid and energy metabolism. Abnormal BAs profiles may be used as biomarkers of several liver diseases. Despite the clinical need of measuring BAs concentration in plasma/serum, reference separations were proved to be unsuitable for simple and rapid analysis. Here is proposed a new LCMS method for the simultaneous high sensitive quantification of 27 BAs. A quick sample preparation technique based on proteins precipitation was applied. Good repeatability was obtained (RSD<5%). Linearity was tested for 16 BAs and confirmed for all in the range 1 to 100 ng/ml. The r<sup>2</sup> coefficients were above 0.99, with S/N>10 for LLOQ levels.

### Materials and Methods

The quantitative analysis of BAs was performed using commercial serum (Seralab, double charcoal stripped) implemented with bile acids standards. Sample preparation procedure (Figure 1.) consists of protein precipitation of the serum sample (100  $\mu$ L) with 5% ammonium hydroxide in acetonitrile, followed by centrifugation at 10000 g for 10 min, nitrogen flow evaporation to dryness and take-up (100  $\mu$ L). The analytes were monitored using UHPLC-MS/MS system (Nexera X2 and LCMS-8060, Shimadzu, Kyoto). The HPLC separation uses a typical C8 reverse phase column (2.7um 2.1x100mm), with 0.2%

formic acid in water as mobile phase A, and methanol : isopropanol 1/1 (v/v) as mobile phase B. Specific external and internal needle rinsing, performed in parallel of the analytical run, ensure the total absence of carryover. MS detection is carried out in negative electrospray ionization, using MRM mode. One to four MRM transitions are monitored per compound, with dwell times between 5 and 32 msec. This provides a minimum of 30 points per chromatographic peak for all BAs. The total analysis run time is 15 min.





Figure 1. Sample workflow overview.

### Excellence in Science

# A novel fast and simple quantification method for bile acids in human serum by LC-MS/MS

### **Typical Chromatograms**

A total of 27 bile acids were simultaneously quantified in a total analysis time of 15 min (Figure 2.). The absence of carryover was also confirmed (residual signal < 0.1% of LLOQ signal in blank sample).



10:Glycocholic acid TIC(-) 11:Omega muricholic acid TIC(-) 12:Alpha muricholic acid TIC(-) 13:Taurochenodeoxycholic acid TIC(-) 14:3-dehydrocholic acid TIC(-) 15:Taurodeoxycholic acid TIC(-) 16:Hyocholic acid TIC(-) 17:Beta muricholic acid TIC(-) 18:Ursodeoxycholic acid TIC(-) 19:Hyodeoxycholic acid TIC(-) 20:Cholic acid TIC(-) 21:Glycochenodeoxycholic acid TIC(-) 22:Glycodeoxycholic acid TIC(-) 23:Chenodeoxycholic acid TIC(-) 24:Taurolithocholic acid TIC(-) 25:Deoxycholic acid TIC(-) 26:Isodeoxycholic acid TIC(-) 27:Lithocholic acid TIC(-)




Figure 2. Typical chromatograms (TIC) for the analysis of 27 bile acids at 1ng/mL in serum

# A novel fast and simple quantification method for bile acids in human serum by LC-MS/MS

## Limits of quantification in serum

Lower limit of quantification (LLOQ) in standard sample was confirmed to be equal or below 1 ng/mL for all 27 BAs (S/N > 10). In serum (Table 1.), LLOQ for 12-dehydrocholic acid is 2.5 ng/mL and is below 1 ng/mL for all other BAs. Good repeatability was obtained at LLOQ level (RSD < 10%).

Compound	LLOQ	S/N	% RSD (n=3)
Tauroalphamuricholic acid	0,01	15	4,3
Taurocholic acid	0,01	18	4,4
Taurohyocholic acid	0,02	17	3,6
Taurochenodeoxycholic acid	0,01	13	7,5
Taurodeoxycholic acid	0,02	11	7,1
Taurodeoxyhyocholic acid	1,0	11	5,2
Tauroursodeoxycholic acid	1,0	12	4,0
Taurolithocholic acid	0,01	17	9,8
Glycocholic acid	0,01	15	3,7
Glycohyocholic acid	0,01	15	2,8
Glycochenodeoxycholic acid	0,02	17	6,1
Glycodeoxycholic acid	0,02	17	4,6
Glycohyodeoxycholic acid	0,02	15	3,7
Glycoursodeoxycholic acid	0,01	13	2,5
Alpha muricholic acid	0,02	15	2,9
Beta muricholic acid	0,03	11	3,1
Cholic acid	0,2	19	2,9
Hyocholic acid	0,05	12	3,0
Omega muricholic acid	0,03	11	2,9
12-dehydrocholic acid	2,5	10	10
3-dehydrocholic acid	0,02	10	2,6
Chenodeoxycholic acid	0,4	10	2,9
Deoxycholic acid	0,3	10	3,8
Hyodeoxycholic acid	0,05	11	2,7
Isodeoxycholic acid	0,02	13	3,2
Ursodeoxycholic acid	0,04	11	2,1
Lithocholic acid	1,0	12	8,9

Table 1. LLOQ of the 27 BAs in serum, and associated signal to noise ratios (S/N) and %RSD values (n=3).

#### A novel fast and simple quantification method for bile acids in human serum by LC-MS/MS

## Linearity

Linearity in serum was tested for 16 BAs and confirmed for all in the range: 1 to 100 ng/mL. Excellent repeatability was obtained (RSD < 5%), as well as good accuracies (85-115%). The  $r^2$  of linearity models were above 0.99 (Figure 3.).

Glycohyodeoxycholic acid

#### Taurohyocholic acid




Figure 3. Examples of standard addition calibration curve obtained for taurohyocholic acid and glycohyodeoxycholic acid.

## Conclusion

A novel LC-MS/MS method was developed for the simultaneous and high sensitive quantification of 27 BAs in human serum, with simple a sample preparation. BAs were quantified in a total analysis time of 15 min with a good distinction between isomers. The method showed good repeatability, linearity and accuracy. The method proved its fits for purpose to monitor changes of BAs profile in metabolism.

For Research Use Only. Not for use in clinical diagnostics.

First Edition: November, 2017



Shimadzu Corporation

www.shimadzu.com/an/

#### For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "@". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.